PORTON | 20th

Small Molecules

Tides

Biologics & Conjugates

Advanced Therapy Medicinal Products

A CUSTOMER-CENTRIC, INNOVATIVE AND RELIABLE CDMO WITH GLOBAL SOLUTIONS

OEB 1 to 5 | Sub-g to Metric-ton Scale | Pre-clinical to Commercial

Enabling the Public's Early Access to Good Medicines

2005-2025

Over the past two decades, Porton has been steadfastly committed to its mission of "Enabling the Public's Early Access to Good Medicines." Through relentless focus on CMC R&D, pioneering pharmaceutical process innovation, and advanced drug manufacturing, we have transformed from a CMO specializing in APIs for MNCs into a globally recognized CDMO leader. Today, we deliver end-to-end, full-lifecycle services operated on a global scale, catering to diverse therapeutic categories with unmatched expertise.

At Porton, our customer-centric ethos is deeply embedded in everything we do. We prioritize "Satisfying Customers and Creating Value" as the cornerstone of our strategic planning and daily operations. It is the unwavering trust of our global clients that has empowered Porton to not only navigate but thrive through market cycles, achieving sustained growth. Of course, this journey would not have been possible without the relentless dedication and ingenuity of our team, nor the steadfast support of investors, and partners who stand beside us.

Looking ahead, Porton is dedicated to proactively navigating the evolving landscape of environmental and geopolitical shifts while harnessing the transformative potential of life sciences and intelligent technologies. We remain committed to technological innovation in pharmaceutical processes, delivering bespoke CDMO solutions that precisely meet the needs of our global clientele. At the same time, we will uphold our core values: "Customers First, Teamwork, Efficient Execution, Embracing Change, and Pursuit of Excellence." Through continuous learning, agile transformation, and operational optimization, we aim to enhance customer satisfaction, streamline workflows, and strengthen organizational resilience. This integrated strategy ensures sustainable, mutually beneficial growth for our clients, employees, investors, partners, and society-ultimately enabling the public's early access to good medicines.

Oliver Ju

Chairman & CEO

About Porton

Porton Pharma Solutions, a global company with R&D and GMP-compliant manufacturing facilities across the US, EU and China, provides customer-centric innovative and reliable CDMO solutions for Small Molecules, Tides, Biologics and Conjugates (ADCs, AOCs, PDCs, RDCs, etc.), and Advanced Therapy Medicinal Products from pre-clinical to commercial stages.

5 Regulated Markets Approval	18 Global Sites	4200+ Global Employees	1200+ R&D and TechOps
~2200 Total Capacity (m^3)	1200+ Global Customers	4000+ Milestone Projects	$ 424 M 2024 Revenue

Data as of December 31, 2024

2005-2008

Started CMO

Changshou (China) Site Started in 2006

2013-2015

Became a Public Company

1st USFDA Inspection Passed and Listed on Shenzhen Stock Exchange

2017-2025

Transformed into a Global Leading CDMO

Acquired J-STAR Research Inc. (USA), Xiaogan Plant (China), Fengxian GMP Plant (China), and Building Slovenia GMP Plant (Europe)

Global Solutions with Capacity in USA, EU and China



Small Molecules CDMO Services

Process Design, Route Scouting, Development and Optimization for APIs and Intermediates

non-GMP and GMP Manufacturing for APIs and Intermediates, Pre-clinical to Commercial

Pre-formulation Research and Process Development & Optimization

GMP Manufacturing for Drug Products, from Pre-clinical to Commercial Batches

Comprehensive Analytical R&D and Quality Control

IND/NDA Dossier and CMC Solutions

Drug Substance Capacity

Site	Reactor Volume (m^3)	Reactor Volume Range (L)	Number of Reactors	Temperature Range (°C)	Reaction Pressure (Bar)	Description
Changshou, Chongqing	1,015	5 to 10,000	381	-93 to 200	-1 to 50	GMP
Fengxian, Shanghai	76	2 to 6,300	81	-80 to 200	-1 to 20	GMP/HP
Yichun, Jiangxi	519	200 to 5,000	221	-70 to 140	-1 to 25	GMP
Xiaogan, Hubei	565	1,000 to 6,300	122	-100 to 150	-1 to 2	non-GMP
New Jersey	1	5 to 150	18	-80 to 220	-1 to 0.95	GMP/HP
Total	2,276	2 to 10,000	823	-100 to 200	-1 to 50	-

Drug Product Capability and Capacity

Cranbury, New Jersey

Solubility Enhancement
- Particle Engineering
- Co-processing

Dosage Form Development
- OSD
- Liquid
- Lyo Powder

GMP Clinical Phase I & II Production
- OSD
- Non-sterile Liquid

Beibei, Chongqing

Tablet	Capsule	Injectable	Semisolid
• IR • MR • Double-layer Tablet	• IR • MR • Micro-pellet Filler	• Ampoule • Vials for Powder & Liquid	• Cream • Ointment • Gel Paste • Gel Patch
• 1 B doses • 60 M doses (HP)	• 200 M doses • 60 M doses (HP)	• 55+ M units	• 50+ M tubes

(Maximum Annual Output Capacity)

Tides CDMO Services

Peptides

- Linear Peptides (<50 aa)
- Cyclic Peptides (<50 aa)
- Peptide Modification
- Key RSMs and Intermediates

Oligonucleotides

- ASO, siRNA
- miRNA
- Aptamer
- sgRNA
- Oligo Modifications

Drug Delivery Materials

- Ionizable Lipids / Cationic Lipids
- Polymers for Drug Delivery
- Complex/Conjugate PolysacCharides
- Other Lipids



Biologics and Conjugates CDMO Services

Conjugates

- ADC
- AOC
- PDC
- RDC

Targeting-vehicle

- Antibody
- Peptide
- Small Molecule

Linker

- Cys (-SH): S-S, Maleimide Group (mc, mcc, etc.)
- Lys (-NH2): Activated Acid (CO-OSu, etc.)
- Short Peptide (VC, GFGG, etc.)

Payload

- Cytotoxic Drugs
- Oligonucleotides
- Radionuclide
- Fluorescers

Advanced Therapy Medicinal Products CRO & CDMO Services

Cell Therapy

- Immune Cell Therapy Products, Including T Cells, NK Cells, and Macrophages
- Stem Cell Therapy Products, Such as MSCs, HSCs, and iPSCs

Viral Vectors

- Lentiviral Vectors
- Adeno-Associated Viral Vectors
- Adenoviral Vectors
- AI-Guided AAV Library Construction and Screening

Plasmid

- Supercoiled Plasmid
- Linear Plasmid
- LcDNA
- Off-the-Shelf GMP Helper Plasmids for Lentiviral Vectors

mRNA

- Non-Replicating mRNA
- Self-Amplifying mRNA
- Circular RNA
- LNP Formulation Library

Investigator-Initiated Clinical Trial Services in China

- Produce Samples for IITs
- Connect with Local Authorities and Medical Institutions
- Support in Reviewing the IIT Study Protocols
- Prepare Documents as a CDMO Partner to Medical Institution for Project Approval and NHC Registry Review
- Support in Finding Reliable Necessary CRO and Medical Writing Partners

Global Presence

Mengeš, Slovenia
R&D and GMP Manufacturing, DS

Copenhagen, Denmark
Office

Turnhout, Belgium
Office

Root, Switzerland
Office

South Plainfield, New Jersey
R&D and GMP Manufacturing, DS

Cranbury, New Jersey
R&D and GMP Manufacturing, HP DS & DP

Chongqing
Headquarters
R&D and GMP Manufacturing
HP DS & DP

Xiaogan
Manufacturing
RSM

Shanghai
Headquarters
R&D and GMP Manufacturing
HP DS & DP
Biologics and Conjugates

Yichun
GMP Manufacturing
DS

Suzhou
R&D and GMP Manufacturing
ATMP

HP: High Potency (OEB 5 <1 μg/m³)
DS: Drug Substance, which is synonymous with Active Pharmaceutical Ingredient (API).
DP: Drug Product, which is synonymous with Finished Dosage Form (FDF).

Porton Pharma Solutions Ltd.
business@portonpharma.com
www.portonpharma.com

Linked in

Contact Us

Global State-of-the-art Technology Platform

Crystallization

Flow Chemistry

Bio Catalysis

Photo & Electrochemistry

Prep-Chromatography

Milling

Metal Catalysis

Chemical Engineering and Technologies

Particle Engineering

- Controlled Particle Formation
  - Crystallization
  - Precipitation (Amorphous)
  - DS-DP Co-processing (Composite)
- Controlled Post Processing
  - Filtration, Drying, Milling, etc.

Material Science

- Solid Form Screen
- Solid-State Chattelization
- Preformulation Evaluation
- Phase Relationship
- Structure Elucidation

Process Engineering

- Separation Processes (Column, Extraction, Distillation, Membrane, Filtration, Drying, etc.)
- Process Simulation
- Process Equipment Selection
- Continuous Process (Design & Control)
- Scale-up / Production De-Risking

Reaction Engineering

- Reaction Kinetics
- Catalysis
- Reaction Simulation
- Reactor Design
- Reaction EHS

Computational Chemistry & Data Science

- Transition State, Reactivity and Selectivity Calculations
- Modeling of Phys-Chem Properties, Drug-Polymer Miscibility, Impurity Rejection
- ML-based DoE Process Optimization
- UV, IR, Raman and NMR Spectra Predictions
- Virtual Screens of Crystallization Process Solvent, Co-Former or Counterion
- AI/ML Data Analysis & Suggestion

Operational Excellence

Intellectual Property

- Audited by 8 of Global Top 20 Pharma (100% Success Rate)
- ISO27001 Information Security Certification

Environmental Health & Safety

- 180+ EHS Audits and Inspections
- 10+ Global Top 20 Pharma EHS Audits
- ISO14001 Environmental Management System
- ISO45001 Occupational Health and Safety Management System

Quality System

- One Porton One Quality System Strictly Following ICH Guidelines
- 5 Authorities GMP Inspections
- 900+ GMP Audits from Customers
- GMP Audits by 17 of Top 20 Global Pharma (100% Success Rate)

FDA U.S. FOOD & DRUG ADMINISTRATION

World Health Organization

EUROPEAN MEDICINES AGENCY SCIENCE MEDICINES HEALTH

PMDA

国家药品监督管理局 National Medical Products Administration

Regulatory Affairs

- 20+ APIs Passed PAI and Approved
- 60+ APIs of Successful PPQ
- 15+ On-going NDA Projects

Project Management

- Customer-centric
- Lifecycle Management
- Efficient and Transparent Communication

Supply Chain

- Supply Chain Visibility
- Back Integration
- Local for Local Supply